

their annual registration using choices on the DRLM menu. Once you choose to register or update your annual registration the system will prompt you through the entry of information about your establishment and your devices. If you have any problems with this process, e-mail: [reglist@cdrh.fda.gov](mailto:reglist@cdrh.fda.gov) or call 301-796-7400 for assistance. (Note: this e-mail address and this telephone number are for assistance with establishment registration only, and not for any other aspects of medical device user fees.) Problems with BER should be directed to [bloodregis@fda.hhs.gov](mailto:bloodregis@fda.hhs.gov) or call 301-827-3546.

#### *D. Step Four—Enter Your DFUF Order PIN and PCN*

After completing your annual or initial registration and device listing, you will be prompted to enter your DFUF order PIN and PCN, when applicable. This process does not apply to licensed biologic devices. CBER will send invoices for payment of the establishment registration fee to companies who only manufacture licensed biologics devices. Fees are only required for those establishments defined in section I of this document.

Dated: July 28, 2009.

**Jeffrey Shuren,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. E9-18456 Filed 7-31-09; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Notice of Meeting; Moving Into the Future—New Dimensions and Strategies for Women's Health Research for the National Institutes of Health**

Notice is hereby given that the Office of Research on Women's Health (ORWH), Office of the Director, National Institutes of Health, Department of Health and Human Services, in collaboration with the Warren Alpert Medical School of Brown University and the Women & Infants Hospital of Rhode Island, will convene a public hearing and scientific workshop on September 21-23, 2009, at the Women & Infants Hospital of Rhode Island Conference Center, Providence, Rhode Island.

#### **Purpose of the Meeting**

With rapid advances in science and wider global understanding of women's health and sex/gender contributions to

well-being and disease, the purpose of the meeting is to ensure that NIH continues to support cutting-edge women's health research that is based upon the most advanced techniques and methodologies. The meeting format is designed to promote an interactive discussion involving leading scientists, advocacy groups, public policy experts, health care providers, and the general public. The Providence meeting is the third in a series that will be convened throughout the Nation to help the ORWH and NIH move into the next decade of women's health research.

As science and technology advance and fields such as computational biology demonstrate the power of interdisciplinary research, it remain critical for sex and gender factors to be integrated into broad experimental methodologies and scientific approaches across the lifespan. Biomedical and behavioral research are also necessary to understand how cultural, ethnic, and racial differences influence the causes, diagnosis, progression, treatment, and outcome of disease among different populations, including women of diverse geographic locations and socioeconomic backgrounds. Furthermore, health differences among diverse populations of women remain a critical area in need of continued focus and attention.

The ORWH challenges all meeting attendees to assist the NIH in defining the women's health research agenda of the future by thinking beyond traditional women's health issues. The ORWH and NIH ask meeting participants to consider creative strategies to identify areas of research that are best poised for advancement, identify innovative ways in which persistent issues of health and disease can be addressed, and explore new horizons of scientific concepts and investigative approaches. Attention also needs to be paid to new areas of science application, new technologies, and continuing basic science investigations. Clinical questions that are not currently the focus of research priorities need to be considered to ensure that women's health research is optimally served and that the ORWH can continue to provide leadership for the benefit of women's health, nationally and internationally.

#### **Meeting Format**

The meeting will consist of public testimony, scientific panels, and eight concurrent scientific working groups. Specifically, on September 21, individuals representing a full spectrum of organizations interested in biomedical and behavioral research on women's health issues will have an

opportunity to provide public testimony from 1:30 to 5:30 p.m. On September 22 and 23, plenary sessions will focus on the intersection of health care, public policy, and biomedical research; on emerging issues and trends in health care; and on research paradigms of the future. The eight concurrent afternoon sessions on September 22 will focus on a range of research areas, including Prenatal, Infancy, and Childhood Years; Adolescent Years; Reproductive and Middle Years; Pregnancy; Menopausal Transition; Elderly, Frail Elderly, and Healthy Aging; Oral Health and Systemic Conditions; and Careers in Dentistry, Bioengineering, and other Non-Medical Disciplines.

On September 23 the morning session will be devoted to reports by the working group co-chairs regarding the recommendations emerging from working group deliberations on the previous day. The meeting will adjourn at 1:15 p.m. on September 23.

#### **Public Testimony**

The ORWH invites individuals with an interest in research related to women's health to provide written and/or oral testimony on these topics and/or on issues related to the sustained advancement of women in various biomedical careers. Due to time constraints, only one representative from an organization or professional specialty group may give oral testimony. Individuals not representing an organized entity but a personal point of view are similarly invited to present written and/or oral testimony. A letter of intent to present oral testimony is necessary and should be sent electronically to <http://www.orwhmeetings.com/movingintothefuture/> or by mail to Ms. Jory Barone, Educational Services, Inc., 4350 East-West Highway, Suite 1100, Bethesda, MD 20814, no later than September 13, 2009. The date of receipt of the communication will establish the order of those selected to give oral testimony at the September meeting.

Those wishing to present oral testimony are also asked to submit a written form of their testimony that is limited to a maximum of 10 pages, double spaced, 12-point font, and should include a brief description of their organization. Electronic submission to the above Web site is preferred; however, for those who do not have access to electronic means, written testimony, bound by the restrictions previously noted and postmarked no later than September 13, 2009, can be mailed to Ms. Jory Barone at the above address. All written presentations must meet the established

page limitations. Submissions exceeding this limit will not be accepted and will be returned. Oral testimony of this material at the meeting will be limited to no more than 5–6 minutes in length.

Because of time constraints for oral testimony, testifiers may not be able to present the complete information as it is contained in their written form submitted for inclusion in the public record for the meeting. Therefore, testifiers are requested to summarize the major points of emphasis from the written testimony, not to exceed 6 minutes of oral testimony. Those individuals or organizations that have indicated they will present oral testimony at the meeting in Providence will be notified prior to the meeting regarding the approximate time for their oral presentation.

Individuals and organizations wishing to provide written statements *only* should send a copy of their statements, electronically or by mail, to the above Web site or address by September 13, 2009. Written testimony received by that date will be made available at the September 21–23 meeting. Logistics questions related to this meeting should be addressed to Ms. Jory Barone at ESI, while program-specific questions should be addressed to Ms. Maureen Pearlman at the Warren Alpert Medical School of Brown University, Providence, Rhode Island, 401–276–7800, ext. 123, [mpearlman@wihri.org](mailto:mpearlman@wihri.org).

At the conclusion of the regional meetings, the ORWH will hold a meeting at the NIH to summarize the deliberations from the regional conferences. The resulting report to the ORWH and the NIH will ensure that women's health research in the coming decade continues to support a vigorous research agenda incorporating the latest advances in technology and cutting-edge science.

Dated: July 28, 2009.

**Raynard S. Kington,**

*Acting Director, National Institutes of Health.*  
[FR Doc. E9–18535 Filed 7–31–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the President's Cancer Panel.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

*Name of Committee:* President's Cancer Panel.

*Date:* September 22, 2009.

*Time:* 8 a.m. to 4:10 p.m.

*Agenda:* America's Demographic and Cultural Transformation: Implications for the Cancer Enterprise.

*Place:* The Westin Seattle, 1900 Fifth Avenue, Seattle, WA 98101.

*Contact Person:* Abby B. Sandler, PhD, Executive Secretary, Chief, Institute Review Office, Office of the Director, 6116 Executive Blvd., Suite 220, MSC 8349, National Cancer Institute, NIH, Bethesda, MD 20892–8349. (301) 451–9399. [sandlera@mail.nih.gov](mailto:sandlera@mail.nih.gov).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: [deainfo.nci.nih.gov/advisory/pcp/pcp.htm](http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm), where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: July 28, 2009.

**Anna Snouffer,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–18531 Filed 7–31–09; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Biomedical Imaging and Bioengineering; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Advisory Council for Biomedical Imaging and Bioengineering.

The meeting will be open to the public as indicated below, with attendance limited to space available.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Council for Biomedical Imaging and Bioengineering, NACBIB, September 2009.

*Date:* September 11, 2009.

*Open:* 9 a.m. to 1 p.m.

*Agenda:* Report from the Institute Director, other Institute Staff and presentations of working group reports.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Closed:* 1 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications and/or proposals.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Anthony Demsey, PhD, Director, National Institute of Biomedical Imaging, and Bioengineering, 6701 Democracy Boulevard, Room 241, Bethesda, MD 20892.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institute's/Center's home page: <http://www.nibib1.nih.gov/about/NACBIB/NACBIB.htm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.701, ARRA Related Biomedical Research and Research Support Awards, National Institutes of Health, HHS)

Dated: July 28, 2009.

**Anna Snouffer,**

*Deputy Director, Office of Federal Advisory Committee Policy.*

[FR Doc. E9–18529 Filed 7–31–09; 8:45 am]

**BILLING CODE 4140–01–P**